With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Dr Rowan French insists lasting weight loss can only be achieved through a balanced approach to psychology, exercise and nutrition.

Debilitating headaches are reducing their quality of life, but doctors say taking these steps can help.

Both GLP-1 drugs, semaglutide is the active ingredient in popular weight-loss drug found in Ozempic and Wegovy, while tirzepatide can be found in Mounjaro and Zepbound.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...